Basic Information
NextVivo is a biotechnology company developing an immune organoid technology platform. Its mission is to accelerate the development of safer and more effective therapies that are generated and tested in immunocompetent human-derived models. NextVivo organoids are miniature 3D cell cultures that mimic the composition, structure, and function of human tissue samples and reproduce key functions of the immune system outside the body. NextVivo's platform can generate cell and antibody therapies and test immunomodulatory drug candidates for various diseases, including cancer, infections, and autoimmune disorders.